Frontlight ResearchEarly access
Taking peoplePhase 1
The REValve Clinical Trial an Evaluation Of the ReValve Palmetto Valve for the Replacement of the Native Mitral VaLVE
Key facts
- Who runs it
- ReValve Solutions Inc.
- Where
- Georgia3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 20 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional
- Treatments tested
- ReValve System
- Record updated
- 29 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Symptomatic MR (≥3+) due to ischemic and non-ischemic cardiomyopathy etiology determined by assessment of a qualifying transthoracic echocardiogram (TTE) obtained within 60 days and transesophageal echocardiogram (TEE) obtained within 90 days prior to subject registration, with MR severity based principally on the TTE study
- New York Heart Association (NYHA) Functional Class II, III or ambulatory IV
- Left Ventricular Ejection Fraction (LVEF) is ≥30% (within 90 days prior to subject registration, assessed by the site using any one of the following methods: echocardiography, contrast left ventriculography, gated blood pool scan or cardiac magnetic resonance imaging (MRI))
- Age greater than 18 years
- Left Ventricular End Systolic Dimension (LVESD) is ≤ 65 mm assessed by site based on a transthoracic echocardiographic (TTE) obtained within 90 days prior to subject consent
Who cannot take part
- Status 1 heart transplant or prior orthotopic heart transplantation
- Cerebrovascular accident within 30 days prior to subject's consent
- Currently participating in an investigational drug or another device study
- Untreated clinically significant coronary artery disease requiring revascularization
- Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
- Known hypersensitivity or contraindication to procedural, post procedural medication (e.g., contrast solution, anticoagulation therapy) or hypersensitivity to nickel or titanium
- Pregnant or planning pregnancy within next 12 months
- Evidence of LV or left atrium (LA) thrombus, vegetation or mass
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Mitral regurgitation
This trial is currently available in Georgia.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
An evaluation of the ReValve System for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.
The group in the trial
- Single Arm StudyTreatment being tested
Treatment: ReValve System
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
Download the PDF
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System
- Criteria questions
- Built from NCT07450911, who can take part
- Record updated
- 29 September 2026